ZyGEM company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

zygem.com

Stage

Asset Sale | AssetsPurchased

About ZyGEM

ZyGEM Corporation produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture.

ZyGEM Headquarter Location

Waikato Innovation Park Ruakura Road

New Zealand

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ZyGEM Patents

ZyGEM has filed 8 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/7/2019

2/18/2020

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

Application Date

2/7/2019

Grant Date

2/18/2020

Title

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Status

Grant

Latest ZyGEM News

ZyGEM NZ Ltd Medical Equipment Deals and Alliances Profile Report Updated 16102018 Prices from USD $250

Dec 2, 2018

00:10 EST 2 Dec 2018 | BioPortfolio Reports Summary ZyGEM NZ Ltd ZyGEM, a subsidiary of MicroGEM International PLC is a drug development company that develops and technologies for life science , agricultural and horticultural industries. The company produces DNA extraction products, and enzymes used in diagnostics, molecular biology and industrial applications. It offers products such as forensicGEM, RNAGEM kits, phytoGEM, prepGEM and PDQeX 2400. ZyGEM's forensicGEM is formulated for DNA extraction from crime samples and CODIS samples. The company's RNAGEM kit produces RNA suitable for direct use in various downstream applications. Its prepGEM is formulated for highthroughput DNA extraction from animal tissue samples. The company's products find application in the fields of forensics, clinical diagnostics, animal livestock genetic testing, environmental, food safety testing, life science research and veterinary. ZyGEM is headquartered in Hamilton, New Zealand. ZyGEM NZ Ltd Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

  • What is ZyGEM's latest funding round?

    ZyGEM's latest funding round is Asset Sale.

  • Who are the investors of ZyGEM?

    Investors of ZyGEM include MicroGEM International.

  • Who are ZyGEM's competitors?

    Competitors of ZyGEM include MolecularMD, Amnis Corporation, ProteinSimple, IntelligentMDx, Evogen, Life Technologies Corporation, BAC, Third Wave Technologies, Protein Discovery, Caliper Life Sciences and 18 more.

You May Also Like

S
SideroGen

SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

O
Occam Research

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

E
Evogen

This company, formerly known as Sceptor, is a global diagnostics, biological collection and detection systems company dedicated to improving the quality of life and world safety by meeting the needs of multiple markets, including research, clinical, environmental and biodefense diagnostics.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

BioGX Logo
BioGX

BioGX, Inc. aims to provide custom assay design and development services and also is currently developing and selling tests for molecular based detection across numerous applications, including, but not limited to: detection of bacteria or viruses in food or the environment, water quality testing (for microbial or viral contamination), testing of foods, plants, and animals, and diverse other applications. Working with the Customer Specific Reagent (CSR) program of Cepheid, Inc., the company also provide conversion of existing assays to a convenient bead format utilizing Cepheid's technology, and custom development of customer-specific applications on Cepheid's platforms. The company provide development services and CSR bead manufacturing support across multiple instrument platforms and detection technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.